Adia Nutrition Inc. Expands Business Model with Licensing Agreements to Meet Global Demand for Adia Med's Regenerative Therapies

Rhea-AI Summary

Adia Nutrition (OTCQB: ADIA) announces expansion of its business model through licensing agreements to meet growing global demand for its regenerative therapies. The company will allow approved clinics worldwide, particularly in the US, Colombia, and Mexico, to operate under the Adia Med brand. Licensed clinics must exclusively source stem cell and exosome products from Adia Labs LLC and maintain Adia Med's quality standards. The program includes access to signature treatments like AdiaVita (100M stem cells, 3T exosomes) and AdiaLink (3.5T exosomes). This strategic move positions Adia Nutrition to capture a larger share of the $15.1B stem cell market while ensuring consistent quality through FDA-registered, cGMP-compliant products.

Positive

• Expansion into new markets through licensing agreements increases revenue potential and market reach
• Mandatory exclusive sourcing from Adia Labs LLC ensures product quality control and recurring revenue stream
• Strategic positioning in the growing $15.1 billion stem cell market
• FDA-registered, cGMP-compliant products enhance credibility and market acceptance

Negative

• Potential risks in maintaining quality control across licensed clinics
• Dependence on third-party clinics for brand reputation management

Winter Park, Florida--(Newsfile Corp. - June 9, 2025) - Adia Nutrition, Inc. (OTCQB: ADIA), a pioneer in regenerative medicine and nutritional supplements, is excited to announce the addition of licensing agreements to its business model, driven by strong demand from clinic owners and doctors worldwide, particularly in countries like the US, Colombia, and Mexico. These licensing agreements complement Adia Nutrition's existing satellite locations, enabling global clinics to deliver Adia Med's innovative regenerative therapies under its trusted brand.

The licensing program allows approved clinics to use the Adia Med name and image, provided they exclusively source their stem cell and exosome products from Adia Labs LLC and maintain the exceptional standards of quality and care that define Adia Med. This ensures patients receive transformative treatments, including AdiaVita (100 million umbilical cord blood-derived stem cells, 3 trillion exosomes) and AdiaLink (3.5 trillion exosomes), synonymous with Adia Med's commitment to excellence.

"Clinic owners and doctors, especially in international markets like the US, Colombia, and Mexico, have eagerly sought to partner with Adia Med," said Larry Powalisz, Chief Executive Officer of Adia Nutrition. "Our licensing agreements empower these clinics to harness our brand and expertise, delivering life-changing regenerative therapies to patients worldwide while upholding our high standards."

Adia Nutrition's expansion strengthens its leadership in the $15.1 billion stem cell market. Licensed clinics will receive robust support, including access to Adia Labs LLC's FDA-registered, 3^rd-party verified, cGMP-compliant products and training to ensure Adia Med's quality. Clinics interested in licensing opportunities are invited to contact Adia Nutrition at ceo@adiamed.com.

For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTCQB: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254608

FAQ

What is Adia Nutrition's new business expansion strategy?

Adia Nutrition is expanding through licensing agreements that allow approved clinics globally to operate under the Adia Med brand, with mandatory sourcing of stem cell and exosome products from Adia Labs LLC.

What products are offered through Adia Med's licensed clinics?

Licensed clinics offer treatments including AdiaVita (100 million umbilical cord blood-derived stem cells, 3 trillion exosomes) and AdiaLink (3.5 trillion exosomes).

Which markets is ADIA targeting for its licensing expansion?

ADIA is primarily targeting markets in the United States, Colombia, and Mexico for its licensing expansion program.

What is the size of the stem cell market that ADIA is entering?

Adia Nutrition is positioning itself in the stem cell market, which is valued at $15.1 billion.

What quality standards must ADIA's licensed clinics maintain?

Licensed clinics must exclusively source products from Adia Labs LLC's FDA-registered, 3rd-party verified, cGMP-compliant facility and maintain Adia Med's standards of quality and care.